NEW YORK (GenomeWeb News) – BG Medicine today reported first quarter revenues of $888,000, up 85 percent from $480,000 in the first quarter of 2012.

The company also announced that it had appointed Paul Sohmer as president and CEO, replacing Eric Bouvier.

The revenue increase was driven by $820,000 in revenues from sales of the company's BGM Galectin-3 test, a 97 percent jump from the $416,000 it posted in Q1 2012. The remaining $68,000 in revenues came from BG's services business, up 6 percent from $64,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.